zurück

Pralsetinib (non-small cell lung cancer (NSCLC), RET-fusion-positive advanced)

Subject:

  • Active Substance: Pralsetinib
  • Name: Gavreto®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Roche Registration GmbH

Time table:

  • Start: 15.12.2021
  • Final decision by G-BA: 16.06.2022

Final decision:

  • Adult patients with PD-L1 expression ≥ 50% of tumor cells; first-line therapy: No additional benefit proved
  • Adult patients with PD-L1 expression ≤ 50% of tumor cells; first-line therapy: No additional benefit proved
  • Adult patients after first-line therapy with a PD-1/PD-L1 antibody as monotherapy: No additional benefit proved
  • Adult patients after first-line therapy with cytotoxic chemotherapy: No additional benefit proved
  • Adult patients after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: No additional benefit proved